PRVB - Provention Bio: The Time Is Right For Teplizumab - High Potential Upside Low Valuation Milestones Approaching

The back half of 2019 was a turbulent ride for small cap biotech stocks largely due to an oversupply of shares via an onslaught of capital raises and IPO’s in the space, coupled with pre-election rhetoric out of Washington threatening drug price regulation.

Source: StockCharts.com

The biotech and small-cap pharma sector is now better capitalized heading into 2020, and so far there is no consensus once again on prescription pricing bills going through Congress, hence the renewed positive sentiment in the sector of late. We expect this run to continue into the beginning of 2020,